Nexliv
Nexliv Products are primarily used for
Liver disease
About Nexliv Products
Uses of Nexliv Products
L-Ornithine L-Aspartate is used in the treatment of liver disease.
Nexliv Products side effects
Common
Side Effect of Nexliv is Injection site reactions (pain, swelling, redness).
How Nexliv Products work
L-Ornithine L-Aspartate is a combination of two amino acids which works by protecting the liver from harmful chemical substances (free radicals), thus preventing liver damage.
Patient Concerns about Nexliv Products
Frequently asked questions about Nexliv Products
Frequently asked questions about L-Ornithine L-Aspartate
Q. Is it ok to take alcohol when taking Nexliv Infusion?
No, it is not recommended to take alcohol when on Nexliv Infusion. It is a medicine given in cases of liver failure. Although, there are no reported interaction. Still, in cases of liver failure, alcohol should be avoided as it could worsen your complication of liver disease.
Q. What is Nexliv Infusion?
Nexliv Infusion is made up of two amino acids. It is most commonly used in cases of liver diseases in order to prevent it from abnormal brain function called hepatic encephalopathy.
Q. What is the use of Nexliv Infusion in the treatment of hepatic encephalopathy (HE)?
Hepatic encephalopathy (HE) is a brain disorder which occurs in patients with liver failure. In liver failure, there is increased bacterial growth in the intestine which leads to an accumulation of ammonia in blood. This deteriorating condition of the liver starts affecting the functioning of the brain, causing Hepatic encephalopathy. Nexliv Infusion works by detoxifying the ammonia from the blood, hence decreasing the free ammonia from the body. This, as a result, helps decrease the abnormal functioning of the brain caused due to liver failure.
Q. How is Nexliv Infusion given?
Nexliv Infusion can be given daily as an injection that is injected into the veins. Your doctor will suggest the appropriate dose depending on the patient’s health condition and severity of the disease.